UCB & ThinkNinja Digital Therapeutics Project

  • Research type

    Research Study

  • Full title

    A randomised controlled trial of a conversational virtual avatar-led cognitive behavioural therapy app intervention for improving the quality of life and mental health of people with epilepsy

  • IRAS ID

    288576

  • Contact name

    Frank Burbach

  • Contact email

    frank.burbach@healios.org.uk

  • Sponsor organisation

    Healios LTD

  • Duration of Study in the UK

    0 years, 6 months, 0 days

  • Research summary

    In this exploratory randomised controlled trial, we will evaluate the clinical effectiveness & benefits of the ThinkNinja for Epilepsy smartphone app as a supportive tool for people with epilepsy. The app was developed & co-produced by experts with clinical expertise in psychological therapy & digital delivery. It is a self-help conversational virtual assistant built on CBT principles. It provides psychoeducation on epilepsy, staying mentally & emotionally well, CBT techniques for anxiety & low mood symptoms, & an ability to track epileptic seizures. The user is guided by a “Wise Ninja” virtual avatar, who assists with the navigation of the app, & who is able to determine when a user requires additional support. In addition, there is a crisis support feature signposting users to emergency telephone numbers. The app has the ability for the user to access further clinical support with a trained clinician via two step-up clinical intervention levels; step-up level 1 is a text-based asynchronous intervention, & step-up level 2 is a live video-based intervention.
    The study aims to enroll 184 adult participants, with clinical levels of anxiety or comorbid anxiety & depression, who have an existing diagnosis of epilepsy. The study will randomly assign participants to one of two conditions – half will receive full access to the ThinkNinja app for 8 weeks, whilst the waiting list control will receive access to the app after 8 weeks.
    Online questionnaires will be completed at baseline, after 4 weeks, 8 weeks, & again at 8 weeks post-study (T3) to collect data regarding participant’s self-reported quality of life, global impression of change & medication adherence. Participant anxiety & depression scores will be captured weekly whilst in the active ThinkNinja arm. Post-study, further participant qualitative feedback on the usage & user experience of ThinkNinja will be obtained through 2-3 focus groups (n=4-8 per group).

  • REC name

    East of England - Cambridge East Research Ethics Committee

  • REC reference

    21/EE/0128

  • Date of REC Opinion

    19 Jul 2021

  • REC opinion

    Further Information Favourable Opinion